CARLSBAD, Calif.--(BUSINESS WIRE)--ArtVentive Medical Group, Inc. (OTCBB: AVTD) announced today that the Company will attend the 18th annual European Vascular Conference (“EVC”) in Maastricht, the Netherlands from May 12th to the 14th and will conduct educational seminars for physicians and its European distribution partner network.
“Dr. Anthony Venbrux, Professor of Radiology and Surgery at George Washington University in Washington DC, will be a keynote speaker at the EVC and address his first-hand experience with the ArtVentive EOS™ device” stated Dr. Leon Rudakov, Artventive’s President and Chief Technology Officer. “In addition, the Company will conduct hands-on training workshops for up to 100 Interventional Specialists focused on the growing applications and deployment of the ArtVentive EOS™.”
Jim Graham, ArtVentive’s Chief Executive Officer stated “the training workshops are an essential component of our high standards and assist our distribution partners and their clinicians in developing a firm understanding of the unique design and clinical benefits of the EOS™ platform. We are excited about this new educational program and look forward to additional initiatives as we continue our commercialization efforts.”
About ArtVentive Medical Group, Inc.
ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device company focused on developing, manufacturing and marketing globally a family of devices featuring the ArtVentive EOS™.
The ArtVentive EOS™ is catheter-based, self-expandable and facilitates permanent or temporary occlusion of peripheral body lumens, cavities occurring within the body’s vascular system and organ network. The ArtVentive EOS™ is designed to serve as a safe and reliable alternative to major surgery in certain cases. This technological innovation brings current interventional, image-guided techniques to a new level of sophistication, with the potential to resolve significant, unaddressed health issues.
The ArtVentive EOS™ serves as a proprietary technology platform for several major clinical areas, including peripheral and neurological vascular disorders, women’s health (minimally invasive contraceptive and birth control), interventional cardiology, pulmonary and interventional oncology procedures.
More information about ArtVentive can be found at www.artventivemedical.com.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to the Company’s current expectations, projections and beliefs concerning matters that are not historical facts. Forward-looking statements are not guarantees of future performance. Forward-looking statements involve uncertainties, risks, assumptions and contingencies, many of which are outside the Company’s control, and, thus, actual results could differ materially from those described in or implied by any forward-looking statement. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. The Company assumes no obligation to update any forward-looking statement made in this news release that becomes untrue because of subsequent events, new information or otherwise, except to the extent it is required to do so in connection with the Company’s ongoing requirements under federal securities laws. For a further discussion of factors that could cause the Company’s future results to differ materially from any forward-looking statements, see the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission.
